PacBio to Participate in the Piper Sandler 37th Annual Healthcare Conference
Rhea-AI Summary
PacBio (NASDAQ: PACB) said management will participate in a fireside chat at Piper Sandler’s 37th Annual Healthcare Conference on Wednesday, December 3, 2025 at 11:30 AM ET in New York.
A live webcast will be available on the company investor site at investor.pacificbiosciences.com, with a replay accessible for at least 30 days after the event.
Positive
- None.
Negative
- None.
News Market Reaction – PACB
In the Nov 28 session, PACB declined 2.93%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Nov 28 | Investor conference | Neutral | -2.9% | Announcement of participation in Piper Sandler healthcare conference with webcast access. |
| Nov 13 | Investor conferences | Neutral | -1.2% | Management scheduled for multiple investor conferences and fireside chats in November. |
| Nov 05 | Earnings update | Neutral | -4.3% | Q3 2025 results with lower revenue but improved margins and lower operating expenses. |
| Nov 05 | Clinical study data | Positive | -4.3% | HiFi Solves consortium study showing strong detection of pathogenic variants with HiFi genomes. |
| Nov 04 | Regulatory approval | Positive | -10.7% | First clinical long-read sequencing regulatory approval in China via Sequel II CNDx system. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Over the last five news events, PACB shares moved lower after all announcements, including positive clinical and regulatory updates, indicating a pattern of negative price reactions to neutral or positive news.
This announcement adds to a series of visibility-focused events for PacBio, following multiple investor conference presentations in mid-November 2025. Earlier in the month, the company reported Q3 2025 results with revenue of $38.4M and improved non-GAAP gross margin of 42%, alongside reduced operating expenses. Clinical and regulatory milestones included a major HiFi Solves consortium study and NMPA Class III approval for the Sequel II CNDx system in China. Despite these developments, PACB’s shares declined after each of these prior announcements.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MENLO PARK, Calif., Nov. 28, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will participate in a fireside chat at Piper Sandler’s 37th Annual Healthcare Conference on Wednesday, December 3, 2025, at 11:30 AM ET in New York, NY.
A live webcast of the event can be accessed at the company’s investors page at investor.pacificbiosciences.com. A replay of the webcast will be available for at least 30 days following the event.
About PacBio
PacBio (NASDAQ: PACB) is a premier life science technology company that designs, develops, and manufactures advanced sequencing solutions to help scientists and clinical researchers resolve genetically complex problems. Our products and technologies, which include our HiFi long-read sequencing, address solutions across a broad set of research applications including human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. For more information, please visit www.pacb.com and follow @PacBio.
PacBio products are provided for Research Use Only. Not for use in diagnostic procedures.
Contacts
Investors:
ir@pacb.com
Media:
pr@pacb.com
